Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective

(2011) A. Tefferi et al.   BLOOD REVIEWS

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

(2011) T. Hornakova et al.   HAEMATOLOGICA

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

(2010) Sachie Marubayashi et al.   JOURNAL OF CLINICAL INVESTIGATION

NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases

(2010) M M Reddy et al.   LEUKEMIA

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation

(2009) Lequn Zhao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains

(2009) Neal K. Williams et al.   JOURNAL OF MOLECULAR BIOLOGY

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

(2009) A. Yoda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

JAK mutations in high-risk childhood acute lymphoblastic leukemia

(2009) C. G. Mullighan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock

(2009) Zsolt Bikadi et al.   Journal of Cheminformatics

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

(2008) G. Wernig et al.   BLOOD

Myeloproliferative disorders

(2008) R. L. Levine et al.   BLOOD

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

(2008) Dani Bercovich et al.   LANCET

BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress

(2008) M Koptyra et al.   LEUKEMIA

Activation of tyrosine kinases by mutation of the gatekeeper threonine

(2008) Mohammad Azam et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY